Filing Flows › Tandem Diabetes Care (TNDM) › Q3 2025
Tandem Diabetes Care (TNDM) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Tandem Diabetes Care (TNDM) reported revenue of $249M for the third quarter 2025 (Q3 2025), +2% from a year earlier and +4% from the quarter before. Operating margin was -9.2%, net loss $21.2M (8.5% of revenue).
Tandem Diabetes Care, Q3 2025: revenue $249M (+2% year over year), operating margin -9.2%, net loss $21.2M, operating cash flow $8.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $249M | +4% | +2% |
| Operating profit | −$22.9M | — | — |
| Net earnings | −$21.2M | — | — |
| Operating cash flow | $8.3M | — | -69% |
| Free cash flow | $4.2M | — | -81% |
What changed
Revenue was $249.3M in Q3 2025, up 2% year over year and up 4% from the previous quarter. Supplies and other was the largest line at 56% of revenue. Supplies and other added $11.0M year over year (up 9%), 208% of the total change. Pump declined 4%.
Gross margin was 53.9%, up 2.8 points from a year earlier. Operating costs exceeded revenue by $22.9M, an operating margin of -9.2%. Operating expenses grew 4% against revenue growth of 2%. The quarter ended with a net loss of $21.2M, narrower than the previous quarter's $52.4M loss.
Operating cash flow was $8.3M (down 69% year over year). Non-cash charges added back $4.5M of depreciation and amortization and $21.1M of share-based compensation. Working capital and other items added $3.8M. Capital expenditures of $4.1M left free cash flow of $4.2M.
Questions
What was Tandem Diabetes Care's revenue in the third quarter 2025?
Tandem Diabetes Care (TNDM) reported revenue of $249M for the third quarter 2025 (Q3 2025), +2% from a year earlier and +4% from the quarter before.
Was Tandem Diabetes Care profitable in the third quarter 2025?
Operating loss was $22.9M (-9.2% of revenue) and net loss $21.2M.